Cambridge Cognition Launches Aqua Automated Quality Assurance Solution
Mixture to be used for central nervous system clinical trials.
Cambridge Cognition announced that it has officially launched Aqua, its automated quality assurance solution for central nervous system (CNS) clinical trials. Powered by the company’s winterlight speech and language platform, the solution is the first product of its kind to be available on the market.
“Aqua is an entirely new solution for the clinical trials market providing a level of quality assurance that was not possible before, from a cost or time perspective, with traditional reviews by medical experts,” said Matthew Stork, CEO, Cambridge Cognition. “We acquired Winterlight Labs intending to commercialize their innovative verbal clinical assessments and, by launching Aqua, we have achieved the first of our product goals. We are also really pleased to have already won a client for Aqua as we expect this will provide us with an excellent case study for future sales.”
Reference: Launch of automated quality assurance for clinical trials. Cambridge Cognition. October 24, 2023. Accessed October 25, 2023. https://cambridgecognition.com/launch-of-automated-quality-assurance-for-clinical-trials/
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
